THE NHS is funding a revolutionary new technology proven to cut the side effects of radiotherapy for prostate cancer patients by 70 percent. The SpaceOAR hydrogel injection – supplied by manufacturer Boston Scientific – has already helped 300,000 patients and will now be rolled out to hospitals across England.
0 comments:
Post a Comment
Note: Only a member of this blog may post a comment.